Physician profile
David Kouri
NPI 1144248618
$728.24
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $264 · 2020: $35.02 · 2021: $326 · 2022: $104.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $419.14 | 2019-2022 | |
| Therapeuticsmd, INC. | $53.91 | 2019-2022 | |
| Scynexis, INC. | $52.02 | 2021-2022 | |
| Boston Scientific Corporation | $46.79 | 2019 | |
| Avion Pharmaceuticals | $43.39 | 2021 | |
| Lupin INC. | $25.82 | 2019-2021 | |
| Avanos Medical | $20.20 | 2019 | |
| Hologic Sales and Service, LLC | $16.75 | 2021 | |
| Organon LLC | $15.38 | 2022 | |
| Mylan Pharmaceuticals INC. | $12.52 | 2022 | |
| Becton, Dickinson and Company | $11.36 | 2021 | |
| Amag Pharmaceuticals, INC. | $10.96 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Kouri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.